ArticleSurgical case reports2026
Apocrine Ductal Carcinoma
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPleomorphic adenoma (PA) of the breast is an extremely rare benign tumor, and malignant transformation within PA is exceptional. Only a few cases have been reported, and none have described apocrine ductal carcinoma CASE PRESENTATION: A 75-year-old woman presented with a 2.0-cm palpable mass in the left breast with nipple inversion. Mammography showed a well-circumscribed 24-mm mass and an adjacent 11-mm lesion with irregular margins near the nipple. MRI demonstrated a cystic lesion with an enhancing mass on the nipple side and nipple retraction toward the lesion. Cytology of cyst fluid revealed no malignant cells and was consistent with a benign hemorrhagic cyst. However, core needle biopsy of the adjacent lesion identified apocrine-type DCIS. Systemic evaluation showed no metastases, and the clinical diagnosis was cTisN0M0, cStage 0 breast cancer. Because nipple involvement could not be excluded, nipple-sparing surgery was not recommended, and the patient underwent mastectomy. Histopathology revealed a well-defined, encapsulated PA containing an intraductal apocrine carcinoma component. The carcinoma cells showed abundant eosinophilic cytoplasm, high nuclear grade, and occasional mitoses without stromal invasion. Immunohistochemically, tumor cells were androgen receptor and Forkhead box protein A1-positive and estrogen- and progesterone receptor-negative, with a Ki-67 index of approximately 30%. The lesion was diagnosed as apocrine-type DCIS ex PA, with ductal extension toward the nipple corresponding to the clinical nipple retraction.
conclusionsWe describe the first reported case of apocrine-type DCIS arising in breast PA. Awareness of this rare entity is essential to avoid misdiagnosis and to clarify its clinicopathological characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.